Shoreline Biosciences Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This Shoreline Biosciences Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP adds recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 21 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply the field and should not be read as evidence of absence.
Executive BD thesis
Shoreline Biosciences presents a practical BD-screening case because its returned pipeline contains 5 records and the deal search returned 3 transaction records. The lead returned asset is iPSC-derived iNK cell therapy (Shoreline Biosciences), associated with a target not returned and Neoplasms, at Preclinical. The immediate objective is not to price a transaction; it is to identify where a focused outreach can unlock regional development, indication expansion, platform access, combination strategy, manufacturing leverage or non-dilutive capital.
The scan prioritizes assets with a named development owner and a traceable stage, then applies a conservative IP screen. A high-quality first meeting should ask for the current clinical/regulatory package, ownership chain, third-party licenses, patent-family schedule, CMC readiness and the specific rights the company is prepared to discuss.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | iPSC-derived iNK cell therapy (Shoreline Biosciences) | Shoreline Biosciences, Inc. | Preclinical | Pipeline record: target not returned; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Gilead, Shoreline partnership ends | Preclinical asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 2 | SLNK12-CARs | Shoreline Biosciences, Inc. | Preclinical | Pipeline record: CD19; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 百济终止细胞疗法合作 | Preclinical asset with CD19 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 3 | Chimeric antigen receptor macrophage therapies(Shoreline Biosciences) | Shoreline Biosciences, Inc. | Discovery | Pipeline record: target not returned; Solid tumor. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Dendreon Pharmaceuticals and Shoreline Biosciences Announce CMC and Manufacturing Alliance to Advance the Future of iPSC Cellular Therapy | Discovery asset with undisclosed target exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 4 | WO2025096718 | Shoreline Biosciences, Inc. | Discovery | Pipeline record: SIRPα; Neoplasms. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | Gilead, Shoreline partnership ends | Discovery asset with SIRPα exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
| 5 | iPSC CAR-NK CD5 (Kite) | Shoreline Biosciences, Inc. | Preclinical | Pipeline record: CD5; Chronic Lymphocytic Leukemia, T-Cell Lymphoma. Confirm CMC, regulatory history, trial registry and data room. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation/delivery claims, platform encumbrances, territory coverage and freedom to operate. | 百济终止细胞疗法合作 | Preclinical asset with CD5 exposure; explore regional rights, co-development, option-to-license or financing-linked structures. |
Shortlist interpretation. The top row should receive the fastest outreach, subject to confirmation that the returned owner and development stage remain current. Rows two through five are option-value workstreams: they can support a regional license, co-development, research collaboration, asset carve-out or structured option if the evidence package is sufficiently differentiated.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage. Those fields should be reconciled against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, safety narratives, manufacturing comparability and the latest investigator or regulator feedback.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across sources. A mismatch is itself a BD signal: it may reflect a recent transfer, dormant program, territory split, combination strategy or portfolio reprioritization. Any mismatch should be resolved before valuation or term-sheet design.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2025-09-03 | Gilead, Shoreline partnership ends | Terminated | total_amount: 2300; disclosed: false |
| 2024-02-27 | 百济终止细胞疗法合作 | Terminated | upfront_payment: 45; disclosed: true |
| 2021-11-04 | Dendreon Pharmaceuticals and Shoreline Biosciences Announce CMC and Manufacturing Alliance to Advance the Future of iPSC Cellular Therapy | Active | disclosed: false |
The most relevant returned precedent is: Gilead, Shoreline partnership ends (2025-09-03). Precedents should guide structure rather than mechanically determine price. Normalize for development stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones and change-of-control provisions. Where economics are undisclosed, the precedent still informs counterparties, strategic intent and preferred transaction form.
Financial capacity and partnering pressure
- Skyline Medical Inc. - Prospectus(U.S. Stocks): Skyline Medical Inc. - Prospectus(U.S. Stocks) NOTE 9 – RELATED PARTY TRANSACTIONS Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations Overview We were incorporated in Minnesota in April 2002. We are a development stage company manufacturing an environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. Since our inception in 2002, we have invested significant resources into product development. We believe that our success depends upon converting the traditional process of collecting and disposing of infectious fluids from the operating rooms of medical facilities to our wall-mounted Fluid Management System (“FMS”) and use of our proprietary cleaning fluid a
- Japan Lifeline Co., Ltd. - Annual securities report-38th Period(2017.04.01-2018.03.31): Japan Lifeline Co., Ltd. - Annual securities report-38th Period(2017.04.01-2018.03.31) ① 重要な会计方针及び见积り これらの资金需要につきましては、営业活动によるキャッシュ・フロー及び自己资金のほか、金融机関からの 借入等による资金调达にて対応していくことを基本としております。なお、中长期的な视野に立った成长投资に つきましては、平成29年12月21日に発行した新株予约権の行使による调达资金を充当する予定であります。ま た、市场及び手元资金等の状况を勘案し、必要と判断した场合には金融机関からの长期借入による対応も検讨し てまいります。 （资金の流动性） 当社グループでは、资金调达の机动性および安定性を高めることを目的として、コミットメントライン契约を 缔结し、流动性リスクに备えております。当连结会计年度末におけるコミットメントラインの総额は85亿円、借 入実行残高は53亿円、借入未実行残高は32亿円となっております。 ４【経営上の重要な契约等】 (1) 海外メーカー等との契约 输入商品について、各メーカー等との间で、输入に系る日本総代理店契约を结んでおります。 主なメーカー等との「総代理店契约」の概要は以下のとおりであります。 (注) １ ソーリンCRM社はエラ・メディカル社が社名変更したものであります。 ２ ソーリン・グループ・イタリア社はソーリン・バイオメディカ・カーディオ社が社名変更したものでありま す。
Financial signals influence timing and leverage. Cash runway, operating burn, committed trial spend, debt covenants, shelf capacity and recent financings determine whether Shoreline Biosciences is more likely to pursue a broad license, regional partnership, cost-sharing collaboration, royalty financing or asset-level option. Figures returned from filings should be rechecked in the latest report before any negotiation.
Recent events and outreach timing
- No company-specific recent-news passage was returned. Confirm the latest clinical, regulatory, financing and leadership events directly with management.
Recent clinical, regulatory, financing, leadership and portfolio events can create a narrow outreach window. The BD team should map each event to a decision owner, an asset-level question and a proposed structure. Avoid generic “partnership interest” messages; lead with the specific program, territory, capability gap and evidence package that the prospective partner can improve.
IP and diligence risk screen
The default IP flag is medium until verified. Review composition-of-matter and sequence claims, method-of-use coverage, formulation and delivery patents, manufacturing know-how, platform licenses, university or government rights, prosecution status, patent-term adjustment/extension, oppositions, litigation, inventorship and freedom to operate. For biologics, cell/gene therapies and platform technologies, background IP and improvement-right provisions can be as important as the asset patents.
Commercial diligence should test addressable population, diagnosis and referral pathway, standard of care, competitor readouts, endpoint sensitivity, payer evidence needs, launch infrastructure and territory-specific regulatory requirements. The value of an asset is a function of the complete evidence package and executable rights—not development stage alone.
Recommended outreach sequence
- Contact the asset-level BD owner with a one-page rationale linked to the lead program and proposed territory or capability contribution.
- Request a non-confidential package covering current stage, dataset maturity, ownership, patent schedule, CMC status and partnering perimeter.
- Benchmark the returned precedents using stage-, modality- and territory-adjusted structures.
- Advance only programs with a coherent owner, evidence package, IP path and decision timeline into confidential diligence.
- Set explicit stop/go gates for data quality, freedom to operate, financing capacity and strategic fit.
Bottom line
Shoreline Biosciences merits targeted BD outreach where the returned pipeline and evidence package align with a partner’s geography, development capability or commercial infrastructure. The recommended next action is to validate iPSC-derived iNK cell therapy (Shoreline Biosciences), confirm rights availability and test a structure calibrated to the company’s financial position and precedent set. The shortlist is designed to turn fragmented intelligence into an actionable owner-by-owner outreach plan.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
